Article Text

Download PDFPDF

Group B streptococcal conjugate vaccines
  1. C J Baker,
  2. M S Edwards
  1. Section of Infectious Diseases, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
  1. Correspondence to:
    Dr M S Edwards, Baylor College of Medicine, One Baylor Plaza, Room 302A, Houston, Texas 77030, USA;
    morvene{at}bcm.tmc.edu

Abstract

Linkage of bacterial capsular polysaccharides to proteins to create conjugate vaccines has had a dramatic impact on the health of children. Although unconjugated polysaccharides are poorly immunogenic in infants and some older children and adults, their covalent coupling with proteins stimulates T cell dependent antigenic recognition that profoundly enhances immunogenicity. In the decade since the introduction and widespread use of Haemophilus influenzae type b polysaccharide conjugate vaccines in the United States, invasive H influenzae infections have become a rarity in childhood.1 Similarly, the conjugation of polysaccharides of Streptococcus pneumoniae to a derivative of diphtheria toxoid and the addition of pneumococcal conjugate vaccine to infant immunisation schedules carries with it promise for a similar decline in the incidence of invasive pneumococcal disease in paediatric patients.2

  • vaccine
  • streptococcus
  • CPS, capsular polysaccharide
  • GBS, group B streptococcus
  • GMC, geometric mean concentration
  • IAP, intrapartum antibiotic prophylaxis
  • TT, tetanus toxoid
View Full Text

Statistics from Altmetric.com

Footnotes

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.